pI: 5.0463 |
Length (AA): 826 |
MW (Da): 85936 |
Paralog Number:
1
Signal peptide: Y | GPI Anchor: | Predicted trans-membrane segments: 14
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_128905)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G15690 | Pyrophosphate-energized vacuolar membrane proton pump 1 |
Arabidopsis thaliana | AT1G16780 | 2 |
Arabidopsis thaliana | AT1G78920 | pyrophosphate-energized membrane proton pump 2 |
Leishmania braziliensis | LbrM.31.1450 | vacuolar-type proton translocating pyrophosphatase 1, putative |
Leishmania donovani | LdBPK_311240.1 | Pyrophosphate-energized vacuolar membrane proton pump 1, putative |
Leishmania infantum | LinJ.31.1240 | vacuolar-type proton translocating pyrophosphatase 1, putative |
Leishmania major | LmjF.31.1220 | vacuolar-type proton translocating pyrophosphatase 1, putative |
Leishmania mexicana | LmxM.30.1220 | vacuolar-type proton translocating pyrophosphatase 1, putative |
Neospora caninum | NCLIV_064810 | hypothetical protein |
Oryza sativa | 4340298 | Os06g0178900 |
Oryza sativa | 4328526 | Os02g0184200 |
Oryza sativa | 4331044 | Os02g0802500 |
Oryza sativa | 4337864 | Os05g0156900 |
Oryza sativa | 4329579 | Os02g0537900 |
Oryza sativa | 4326846 | Os01g0337500 |
Oryza sativa | 4341645 | Os06g0644200 |
Plasmodium berghei | PBANKA_1449800 | inorganic pyrophosphatase, putative |
Plasmodium berghei | PBANKA_1320500 | V-type H(+)-translocating pyrophosphatase, putative |
Plasmodium falciparum | PF3D7_1235200 | V-type K+-independent H+-translocating inorganic pyrophosphatase |
Plasmodium falciparum | PF3D7_1456800 | V-type H(+)-translocating pyrophosphatase, putative |
Plasmodium knowlesi | PKNH_1454900 | vacuolar-type H+-translocating inorganic pyrophosphatase, putative |
Plasmodium knowlesi | PKNH_1225000 | V-type H(+)-translocating pyrophosphatase, putative |
Plasmodium vivax | PVX_117625 | V-type H(+)-translocating pyrophosphatase, putative |
Plasmodium vivax | PVX_100710 | vacuolar-type H+ pumping pyrophosphatase, putative |
Plasmodium yoelii | PY06858 | V-type H(+)-translocating pyrophosphatase |
Plasmodium yoelii | PY00513 | vacuolar-type H+ pumping pyrophosphatase-related |
Trypanosoma brucei gambiense | Tbg972.4.4470 | vacuolar-type proton translocating pyrophosphatase 1, putative |
Trypanosoma brucei gambiense | Tbg972.8.8300 | vacuolar-type proton translocating pyrophosphatase 1 |
Trypanosoma brucei | Tb927.8.7980 | Pyrophosphate-energized vacuolar membrane proton pump 2, putative |
Trypanosoma brucei | Tb927.4.4380 | Pyrophosphate-energized vacuolar membrane proton pump 1 |
Trypanosoma congolense | TcIL3000_0_60300 | vacuolar-type proton translocating pyrophosphatase 1 |
Trypanosoma cruzi | TcCLB.511385.30 | vacuolar-type proton translocating pyrophosphatase 1 |
Trypanosoma cruzi | TcCLB.510773.20 | Vacuolar proton pyrophosphatase 1, putative |
Toxoplasma gondii | TGME49_248670 | V-type H(+)-translocating pyrophosphatase VP1 |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.8.7980 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.7980 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.7980 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.8.7980 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb927.4.4380 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.4.4380 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.4.4380 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.4.4380 this record | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_1320500 | Plasmodium berghei | Slow | plasmo |
PBANKA_1449800 | Plasmodium berghei | Dispensable | plasmo |
TGME49_248670 | Toxoplasma gondii | Probably non-essential | sidik |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in procyclic forms . | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Compound | Source | Reference |
---|---|---|
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References | |
ChEMBL23 | References |
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Trypanosoma brucei | Pyrophosphate-energized vacuolar membrane proton pump 2, putative | Compounds | References |
Trypanosoma brucei gambiense | vacuolar-type proton translocating pyrophosphatase 1, putative | Compounds | References |
Target | Type | Source | Notes |
---|---|---|---|
Tb927.4.4380 | purified protein | BRENDA | A protein with this EC number or name or sequence has been purified from Trypanosoma brucei ( 1 ) |
9 literature references were collected for this gene.